Ildikó Istenes

Ildikó Istenes

Auto-generated profile, based on publicly available information

Ildikó Istenes

Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2013 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
IIIldikó Istenes
Ildikó Istenes
AKAnna Erzsébet Körei
Anna Erzsébet Körei
ZPZsuzsanna Putz
Zsuzsanna Putz
NNNóra Németh
Nóra Németh
TMTimea Martos
Timea Martos
PKPéter Kempler
Péter Kempler

28 May 2021 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
OVOrsolya E. Vági
Orsolya E. Vági
MSMárk M. Svébis
Márk M. Svébis
BDBeatrix A. Domján
Beatrix A. Domján
AKAnna Körei
Anna Körei
IIIldikó Istenes
Ildikó Istenes
ATAdam Tabak
Adam Tabak
Background. People with diabetic cardiovascular autonomic neuropathy (CAN) have increased cardiovascular mortality. However, the association between distal symmetric polyneuropathy (DSPN) or CAN with all-cause mortality is much less investigated. Thus, we set out to examine the effect of CAN and DSPN on all-cause mortality in a well-phenotyped cohort. Methods. All diabetes cases ( n = 1,347 ) from the catchment area of a secondary diabetes care centre who had medical examination including neuropathy assessment between 1997 and 2016 were followed up for all-cause mortality in the NHS Hungary reimbursement database until 2018. We investigated the association of CAN (Ewing tests) and DSPN (Neurometer) with all-cause mortality using Cox models stratified by diabetes type. Results. Altogether, n = 131 / 1,011 persons with type 1/type 2 diabetes were included. Of the participants, 53%/43% were male, mean age was 46 ± 12 / 64 ± 10 years, diabetes duration was 13 ± 10 / 7 ± 8 years, 42%/29% had CAN, and 39%/37% had DSPN. During the 9 ± 5 / 8 ± 5 -year follow-up, n = 28 / 494 participants died. In fully adjusted models, participants with type 1 diabetes patients with versus without DSPN had an increased mortality (HR 2.99, 95% CI 1.4-8.63), while no association with CAN was observed. In type 2 diabetes, both DSPN and CAN independently increased mortality (HR 1.32, 95% CI: 1.07-1.64, and HR 1.44, 95% CI: 1.17-1.76). Conclusions. Our results are compatible with an increased risk of mortality in people with type 1 diabetes and DSPN. Furthermore, we report a similarly strong association between DSPN and CAN and all-cause mortality in type 2 diabetes mellitus.

Verified
Journal Article
Open access
PDF file
DTDóra Zsuszanna Tordai
Dóra Zsuszanna Tordai
NHNoémi Hajdú
Noémi Hajdú
RRRamóna Rácz
Ramóna Rácz
IIIldikó Istenes
Ildikó Istenes
MBMagdolna Békeffy
Magdolna Békeffy
ZPZsuzsanna Zsuzsanna Putz
Zsuzsanna Zsuzsanna Putz
Neuropathy is a serious and frequent complication of type 2 diabetes (T2DM). This study was carried out to search for genetic factors associated with the development of diabetic neuropathy by whole exome sequencing. For this study, 24 patients with long-term type 2 diabetes with neuropathy and 24 without underwent detailed neurological assessment and whole exome sequencing. Cardiovascular autonomic function was evaluated by cardiovascular reflex tests. Heart rate variability was measured by the triangle index. Sensory nerve function was estimated by Neurometer and Medoc devices. Neuropathic symptoms were characterized by the neuropathy total symptom score (NTSS). Whole exome sequencing (WES) was performed on a Thermo Ion GeneStudio S5 system determining the coding sequences of approximately 32,000 genes comprising 50 million base pairs. Variants were detected by Ion Reporter software and annotated using ANNOVAR, integrating database information from dbSNP, ClinVar, gnomAD, and OMIM. Integrative genomics viewer (IGV) was used for visualization of the mapped reads. We have identified genetic variants that were significantly associated with increased (22–49-fold) risk of neuropathy (rs2032930 and rs2032931 of recQ-mediated genome instability protein 2 (RMI2) gene), rs604349 of myosin binding protein H like (MYBPHL) gene and with reduced (0.07–0.08-fold) risk (rs917778 of multivesicular body subunit 12B (MVB12B) and rs2234753 of retinoic acid X receptor alpha (RXRA) genes). The rs2032930 showed a significant correlation with current perception thresholds measured at 5 Hz and 250 Hz for n. medianus (p = 0.042 and p = 0.003, respectively) and at 5 Hz for n. peroneus (p = 0.037), as well as the deep breath test (p = 0.022) and the NTSS (p = 0.023). The rs2032931 was associated with current perception thresholds (p = 0.003 and p = 0.037, respectively), deep breath test (p = 0.022), and NTSS (p = 0.023). The rs604349 correlated with values measured at 2000 (p = 0.049), 250 (p = 0.018), and 5 Hz (p = 0.005) for n. medianus, as well as warm perception threshold measured by Medoc device (p = 0.042). The rs2234753 showed correlations with a current perception threshold measured at 2000 Hz for n. medianus (p = 0.020), deep breath test (p = 0.040), and NTSS (p = 0.003). There was a significant relationship between rs91778 and cold perception threshold (p = 0.013). In our study, genetic variants have been identified that may have an impact on the risk of neuropathy developing in type 2 diabetic patients. These results could open up new opportunities for early preventive measures and might provide targets for new drug developments in the future.

Verified
Journal Article
Open access
PDF file
NHNoémi Hajdú
Noémi Hajdú
RRRamóna Rácz
Ramóna Rácz
DTDóra Zsuzsanna Tordai
Dóra Zsuzsanna Tordai
MBMagdolna Békeffy
Magdolna Békeffy
OVOrsolya Erzsébet Vági
Orsolya Erzsébet Vági
ZPZsuzsanna Zsuzsanna Putz
Zsuzsanna Zsuzsanna Putz
The exact mechanism by which diabetic neuropathy develops is still not fully known, despite our advances in medical knowledge. Progressing neuropathy may occur with a persistently favorable metabolic status in some patients with diabetes mellitus, while, in others, though seldom, a persistently unfavorable metabolic status is not associated with significant neuropathy. This might be significantly due to genetic differences. While recent years have brought compelling progress in the understanding of the pathogenetic background—in particular, accelerated progress is being made in understanding molecular biological mechanisms—some aspects are still not fully understood. A comparatively small amount of information is accessible on this matter; therefore, by summarizing the available data, in this review, we aim to provide a clearer picture of the current state of knowledge, identify gaps in the previous studies, and possibly suggest directions for future studies. This could help in developing more personalized approaches to the prevention and treatment of diabetic neuropathy, while also taking into account individual genetic profiles.

Verified
Journal Article
Open access
PDF file
NHNoémi Hajdú
Noémi Hajdú
DTDóra Zsuzsanna Tordai
Dóra Zsuzsanna Tordai
RRRamóna Rácz
Ramóna Rácz
ZLZsófia Ludvig
Zsófia Ludvig
IIIldikó Istenes
Ildikó Istenes
ZPZsuzsanna Putz
Zsuzsanna Putz
The pathogenesis of diabetic neuropathy involves complex interactions between metabolic and genetic factors. This study aimed to identify novel genetic variants associated with neuropathy risk in type 2 diabetes through reanalysis of whole-exome sequencing data. We identified seven new SNPs with significant associations, including intronic variants in TTN, PLCB1, CCNI, and CDC34 and a 5′-upstream variant in BTG2. These variants are implicated in muscle elasticity, neurotransmission, endothelial regeneration, and apoptosis resistance, suggesting multifaceted genetic contributions to neuropathy development. These findings enhance our understanding of diabetic neuropathy and may support future advances in risk stratification and therapy development.

29 April 2022 in Pathology and Oncology Research
Verified
Journal Article
Open access
ZNZsófia Flóra Nagy
Zsófia Flóra Nagy
KFKata Ferenczi
Kata Ferenczi
IIIldikó Istenes
Ildikó Istenes
HEHanna Eid
Hanna Eid
CBCsaba Bödör
Csaba Bödör
JDJudit Demeter
Judit Demeter
Hairy cell leukaemia (HCL) is a rare B cell malignancy with an indolent course leading to pancytopaenia due to bone marrow infiltration. It has been proposed that HCL patients are at risk of developing a secondary malignancy, with a marked likelihood of the development of other hematologic malignancies including Hodgkin lymphoma and high-grade non-Hodgkin lymphomas. Here, we present the case of two patients who developed diffuse large B cell lymphoma after a long course of hairy cell leukaemia. In the case of the female patient, we report on the occurrence of a third malignant disease, which is very uncommon. With our case descriptions we contribute to the very small number of similar cases reported.